Physician profile
Melissa Mann
NPI 1730706243
$804.10
in general payments reported to CMS, 2019-2025
20 companies · $90.94 in 2025
The $90.94 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $170 · 2021: $262 · 2022: $242 · 2023: $40.03 · 2025: $90.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.46 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $90.20 | 2022-2025 | Airsupra |
| Lilly USA, LLC | $84.75 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $72.00 | 2022 | |
| Amarin Pharma, INC. | $71.37 | 2020 | |
| Abbott Laboratories | $61.95 | 2021 | |
| Mylan Specialty L.P. | $44.69 | 2020-2021 | |
| Amgen INC. | $40.66 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.41 | 2022-2023 | Lynparza, Keytruda |
| Electromed, INC. | $28.81 | 2025 | Smartvest |
| Abbvie INC. | $27.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $27.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.00 | 2022 | |
| Exelixis INC. | $21.04 | 2023 | Cabometyx |
| Csl Behring | $17.81 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.05 | 2022 | |
| Daiichi Sankyo INC. | $14.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.